

TTFields (NovoTTF-200T) LUNAR

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



TTFields (NovoTTF-200T) LUNAR

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
 Therapeutic Indication: Addition of tumor-treating fields (TTFields) to standard-of-care (SOC) therapies in patients with non-small cell lung cancer (NSCLC) after disease progression on or following platinum-based treatment
 Experimental Arm: TTFields (NovoTTF-200T) + Standard systemic therapy (investigator's choice of immune checkpoint inhibitor [nivolumab, pembrolizumab, or atezolizumab] or docetaxel)
 Control Arm: Standard therapy alone



